AMOXICILLIN description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

AMOXICILLIN

STAT Rx USA LLC

AMOXICILLIN powder, for suspension


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

AMOXICILLIN DESCRIPTION

Formulations of amoxicillin for oral suspension, USP contain amoxicillin, a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Chemically, it is (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. It may be represented structurally as:


AMOXICILLIN

1619352





CLINICAL PHARMACOLOGY

Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of amoxicillin from the suspension of amoxicillin has been partially investigated. The 400 mg formulation has been studied only when administered at the start of a light meal. Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. The half-life of amoxicillin is 61.3 minutes. Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenecid. In blood serum, amoxicillin is approximately 20%  protein-bound.
 
Orally administered doses of amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3 mcg/mL and 3.5 mcg/mL to 5 mcg/mL, respectively.
 
Detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. Following a 1 gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid. Approximately 60%  of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours.

Microbiology

Amoxicillin is similar to ampicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. Amoxicillin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.


Enterococcus faecalis
Staphylococcus
Streptococcus pneumoniae
Streptococcus


Escherichia coli
Haemophilus influenzae
Neisseria gonorrhoeae
Proteus mirabilis

Helicobacter pylori

1ampicillinS. pneumoniaeS. pneumoniae



Enterococcus
   MIC (mcg/mL)   
   Interpretation   
≤8
   Susceptible   (S)
≥16
   Resistant       (R)   
Staphylococcusa
   MIC (mcg/mL)   
   Interpretation   
≤0.25
   Susceptible   (S)
≥0.5
   Resistant       (R)   
Streptococcus S. pneumoniae
   MIC (mcg/mL)   
   Interpretation   
≤0.25
   Susceptible    (S)   
0.5 to 4
   Intermediate  (I)
≥8
   Resistant       (R)
S. pneumoniaeb
Amoxicillin
   MIC (mcg/mL)   
   Interpretation   
≤2
   Susceptible     (S)   
4
   Intermediate   (I)
≥8
   Resistant        (R)
NOTE:



   MIC (mcg/mL)   
   Interpretation
≤8
   Susceptible     (S)      
16
   Intermediate   (I)
≥32
   Resistant        (R)
H. influenzae
   MIC (mcg/mL)   
   Interpretation   
≤1
   Susceptible    (S)   
2
   Intermediate  (I)
≥4
   Resistant       (R)


H. influenzae Haemophilus1



ampicillin
Microorganism
   MIC Range (mcg/mL)   
   E. coli                        ATCC 25922
2 to 8
   E. faecalis                 ATCC 29212
0.5 to 2
   H. influenzae            ATCC 49247d   
2 to 8
   S. aureus                   ATCC 29213
0.25 to 1
amoxicillin
Microorganism
   MIC Range (mcg/mL)   
   S. pneumoniae         ATCC 49619e   
0.03 to 0.12

1
S. pneumoniae
2S. pneumoniaeampicillin





Enterococcus

   Zone Diameter (mm)   
   Interpretation   
≥17
   Susceptible   (S)   
≤16
   Resistant       (R)

Staphylococcus f


   Zone Diameter (mm)   
   Interpretation   
≥29
   Susceptible   (S)   
≤28
   Resistant       (R)

β-hemolytic streptococci


   Zone Diameter (mm)   
   Interpretation   
≥26
   Susceptible     (S)   
19 to 25
   Intermediate   (I)
≤18
   Resistant        (R)

NOTE:Spneumoniae


S. pneumoniae


S. pneumoniae
S. pneumoniae




   Zone Diameter (mm)   
   Interpretation   
≥17
   Susceptible     (S)   
14 to 16
   Intermediate   (I)
≤13
   Resistant        (R)

H. influenzae g


   Zone Diameter (mm)   
   Interpretation
≥22
   Susceptible      (S)   
19 to 21
   Intermediate    (I)
≤18
   Resistant         (R)


H. influenzaeHaemophilus2



ampicillin
Microorganism
   Zone Diameter (mm)   
   E. coli                       ATCC 25922
16 to 22
   H. influenzae            ATCC 49247h   
13 to 21
   S. aureus                   ATCC 25923
27 to 35

Using 1 mcg oxacillin disk:


Microorganism
   Zone Diameter (mm)   
   S. pneumoniae          ATCC 49619i   
8 to 12

H. influenzae2
S. pneumoniae2
In vitroH. pylori

AMOXICILLIN INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
 
Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below:

Infections of the ear, nose, and throat
 – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Infections of the genitourinary tract
 – due to E. coli, P. mirabilis, or E. faecalis.

Infections of the skin and skin structure
 – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli.

Infections of the lower respiratory tract
 – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Gonorrhea, acute uncomplicated (ano-genital and urethral infections)
 – due to N. gonorrhoeae (males and females).


H. pyloriH. pyloriH. pylori CLINICAL STUDIES DOSAGE AND ADMINISTRATION
H. pyloriwho are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected.H. pylori CLINICAL STUDIES DOSAGE AND ADMINISTRATION

AMOXICILLIN CONTRAINDICATIONS

A history of allergic reaction to any of the penicillins is a contraindication.

WARNINGS

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. ALTHOUGH ANAPHYLAXIS IS MORE FREQUENT FOLLOWING PARENTERAL THERAPY, IT HAS OCCURRED IN PATIENTS ON ORAL PENICILLINS. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH AMOXICILLIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, AMOXICILLIN SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.
 
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
 
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
 
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS


General

The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur, amoxicillin should be discontinued and appropriate therapy instituted.
 
A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash. Thus, ampicillin-class antibiotics should not be administered to patients with mononucleosis.
 
Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Amoxicillin may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed.
 
Patients should be counseled that antibacterial drugs, including amoxicillin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When amoxicillin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin or other antibacterial drugs in the future.
 
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Laboratory Tests

As with any potent drug, periodic assessment of renal, hepatic, and hematopoietic function should be made during prolonged therapy.

All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with amoxicillin should have a follow-up serologic test for syphilis after 3 months.

Drug Interactions

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.
 
Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. This has been demonstrated in vitro; however, the clinical significance of this interaction is not well documented.
 
In common with other antibiotics, amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

Drug/Laboratory Test Interactions

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST®, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX®) be used.
 
Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted. This effect may also occur with amoxicillin.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate. Amoxicillin and clavulanic acid mixture was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and clavulanic acid mixture was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and clavulanic acid mixture was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 3 times the human dose in mg/m2).

Pregnancy


Labor and Delivery

Oral ampicillin-class antibiotics are poorly absorbed during labor. Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions but moderately increased the height and duration of contractions. However, it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

Nursing Mothers

Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.


Pediatric Use

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (≤3 months). (See DOSAGE AND ADMINISTRATION: Neonates and Infants .)

Geriatric Use

An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. Of the 1,811 subjects treated with capsules of amoxicillin, 85% were less than 60 years old, 15% were ≥61 years old and 7% were ≥71 years old. This analysis and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

AMOXICILLIN ADVERSE REACTIONS

As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever, or urticaria. The following adverse reactions have been reported as associated with the use of penicillins:

Infections and Infestations

Mucocutaneous candidiasis.

Gastrointestinal

Nausea, vomiting, diarrhea, black hairy tongue, and hemorrhagic/pseudomembranous colitis.
 
Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. (See WARNINGS .)

Hypersensitivity Reactions

Anaphylaxis (See WARNINGS .)
 
Serum sickness–like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis and urticaria have been reported.

NOTE: 
These hypersensitivity reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, amoxicillin should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to amoxicillin therapy.

Liver

A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.

Renal

Crystalluria has also been reported (see OVERDOSAGE ).

Hemic and Lymphatic Systems

Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

Central Nervous System

Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported rarely.

Miscellaneous

Tooth discoloration (brown, yellow, or gray staining) has been rarely reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

Combination Therapy with Clarithromycin and Lansoprazole

In clinical trials using combination therapy with amoxicillin plus clarithromycin and lansoprazole, and amoxicillin plus lansoprazole, no adverse reactions peculiar to these drug combinations were observed. Adverse reactions that have occurred have been limited to those that had been previously reported with amoxicillin, clarithromycin, or lansoprazole.





OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.3
 
Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.
 
Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.
 
Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.

AMOXICILLIN DOSAGE AND ADMINISTRATION

Oral suspensions of amoxicillin may be given without regard to meals. The 400 mg suspension has been studied only when administered at the start of a light meal.

Neonates and Infants Aged ≤12 Weeks (≤3 Months)

Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin is 30 mg/kg/day divided q12h.

Adults and Pediatric Patients >3 Months


   Infection     Severity *     Usual Adult Dose     Usual Dose for Children >3 Months+
       
   Ear/Nose/Throat      Mild/Moderate
    500 mg every 12 hours      25 mg/kg/day in divided
       or 250 mg every 8 hours       doses every 12 hours 
         or
         20 mg/kg/day in divided
         doses every 8 hours 
       
     Severe
    875 mg every 12 hours      45 mg/kg/day in divided 
       or 500 mg every 8 hours        doses every 12 hours 
         or 
         40 mg/kg/day in divided 
         doses every 8 hours 
       
   Lower Respiratory Tract   
    Mild/Moderate or Severe    
    875 mg every 12 hours      45 mg/kg/day in divided 
       or 500 mg every 8 hours     doses every 12 hours 
         or
         40 mg/kg/day in divided 
         doses every 8 hours 
       
   Skin/Skin Structure
    Mild/Moderate
    500 mg every 12 hours     25 mg/kg/day in divided 
       or 250 mg every 8 hours     doses every 12 hours 
         or
         20 mg/kg/day in divided 
         doses every 8 hours 
       
     Severe
    875 mg every 12 hours      45 mg/kg/day in divided 
       or 500 mg every 8 hours     doses every 12 hours 
         or
         40 mg/kg/day in divided 
         doses every 8 hours 
       
   Genitourinary Tract
    Mild/Moderate
    500 mg every 12 hours      25 mg/kg/day in divided 
       or 250 mg every 8 hours     doses every 12 hours 
         or
         20 mg/kg/day in divided 
         doses every 8 hours 
     Severe
    875 mg every 12 hours      45 mg/kg/day in divided 
       or 500 mg every 8 hours     doses every 12 hours 
         or
         40 mg/kg/day in divided 
         doses every 8 hours 
       
   Gonorrhea Acute,        3 grams as single oral      Prepubertal children:   50 
   uncomplicated       dose        mg/kg amoxicillin, 
   ano-genital and         combined with 25 mg/kg 
   urethral infections         probenecid as a single dose.
   in males and         NOTE: SINCE
   females         PROBENECID IS
         CONTRAINDICATED
         IN CHILDREN UNDER 
         2 YEARS, DO NOT USE    
         THIS REGIMEN IN
         THESE CASES. 

* Dosing for infections caused by less susceptible organisms should follow the recommendations for severe infections.
+The children's dosage is intended for individuals whose weight is less that 40 kg or more should be dosed according to the adult recommendations.

After reconstitution, the required amount of suspension should be placed directly on the child’s tongue for swallowing. Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately. To be certain the child is receiving full dosage, such preparations should be consumed in entirety.
 
All patients with gonorrhea should be evaluated for syphilis. (See PRECAUTIONS: Laboratory Tests .)
 
Larger doses may be required for stubborn or severe infections.

General

It should be recognized that in the treatment of chronic urinary tract infections, frequent bacteriological and clinical appraisals are necessary. Smaller doses than those recommended above should not be used. Even higher doses may be needed at times. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. Except for gonorrhea, treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days’ treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.

H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence


INDICATIONS AND USAGE
INDICATIONS AND USAGE

Dosing Recommendations for Adults with Impaired Renal Function

Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Patients with a glomerular filtration rate of 10 to 30 mL/min. should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection. Patients with a less than 10 mL/min. glomerular filtration rate should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.
 
Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

There are currently no dosing recommendations for pediatric patients with impaired renal function.

Directions for Mixing Oral Suspension

Prepare suspension at time of dispensing as follows: Tap bottle until all powder flows freely. Add approximately 1/3 of the total amount of water for reconstitution (see table below) and shake vigorously to wet powder. Add remainder of the water and again shake vigorously.

                                             200 mg/5 mL
                                                                                           Amount of Water
   Bottle Size                                                                  Required for Reconstitution
     50 mL                                                                                       35 mL
     75 mL                                                                                       52 mL
   100 mL                                                                                       69 mL

Each teaspoonful (5 mL) will contain 200 mg amoxicillin.
 
                                            400 mg/5 mL

                                                                                          Amount of Water
   Bottle Size                                                                  Required for Reconstitution
     50 mL                                                                                       35 mL
     75 mL                                                                                       52 mL
   100 mL                                                                                       69 mL

Each teaspoonful (5 mL) will contain 400 mg amoxicillin.

NOTE:  SHAKE ORAL SUSPENSION WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration preferable, but not required.

HOW SUPPLIED

Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted bubble-gum-flavored pink suspension contains 200 or 400 mg amoxicillin as the trihydrate.

                                             200 mg/5 mL

 
                  50 mL bottle                                               NDC 65862-070-50
                  75 mL bottle                                               NDC 65862-070-75
                100 mL bottle                                               NDC 65862-070-01

                                             400 mg/5 mL

 
                  50 mL bottle                                               NDC 65862-071-50
                  75 mL bottle                                               NDC 65862-071-75
                100 mL bottle                                               NDC 65862-071-01

Store dry powder at
20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

CLINICAL STUDIES


H. pyloriH. pylori








H. pylori Eradication Rates - Triple Therapy (amoxicillin/clarithromycin/lansoprazole)
Percent of Patients Cured [95% Confidence Interval]  (Number of Patients)


 Triple Therapy  Triple Therapy
   Study Evaluable Analysis*   Intent-to-Treat Analysis† 



   Study 1                                92‡   86‡ 

[80 - 97.7] [73.3 - 93.5]

(n = 48) (n = 55)



   Study 2   86§   83§ 

[75.7 - 93.6] [72 - 90.8]

(n = 66) (n = 70)






H. pylori Eradication Rates – Dual Therapy (amoxicillin/lansoprazole) Percent of Patients Cured [95% Confidence Interval] (Number of Patients)


 Dual Therapy  Dual Therapy
   Study Evaluable Analysis*  Intent-to-Treat Analysis† 



   Study 1                                   77‡   70‡ 

[62.5 - 87.2] [56.8 - 81.2]

(n = 51) (n = 60)
 

   Study 2   66§   61§ 

[51.9 - 77.5] [48.5 - 72.9]

(n = 58) (n = 67)







REFERENCES

  • National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically – Fourth Edition; Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2. NCCLS, Wayne, PA, January 1997.
  • National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests – Sixth Edition; Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1. NCCLS, Wayne, PA, January 1997.
  • Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988;30:66-67.     






Aurobindo Pharma USA, Inc.




Aurobindo Pharma Limited


AMOXICILLIN POWDER FOR SUSPENSION  400MG / 5mL


AMOXICILLIN


AMOXICILLIN

AMOXICILLIN POWDER, FOR SUSPENSION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:16590-401(NDC:65862-071)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
AMOXICILLIN amoxicillin anhydrous 400 mg

Inactive Ingredients

Ingredient Name Strength
SUCROSE
TRISODIUM CITRATE DIHYDRATE
SODIUM BENZOATE
EDETATE DISODIUM
FD&C RED NO. 3
XANTHAN GUM
SILICON DIOXIDE

Product Characteristics

Color
pink

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:16590-401-32 100 in 1 BOTTLE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065334 2006-12-28


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.